Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxoprubart in Soliris-Treated PNH
NCT05731050Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ruxoprubart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by NovelMed Therapeutics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05731050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731050.